These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
New York
|
|
13-1432060
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
Large accelerated filer
|
þ
|
Accelerated filer
|
¨
|
|
Non-accelerated filer
|
¨
|
Smaller reporting company
|
¨
|
|
|
|
Emerging growth company
|
¨
|
|
(DOLLARS IN THOUSANDS)
|
March 31, 2018
|
|
December 31, 2017
|
||||
|
ASSETS
|
|
|
|
||||
|
Current Assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
305,276
|
|
|
$
|
368,046
|
|
|
Trade receivables (net of allowances of $13,484 and $13,392, respectively)
|
734,378
|
|
|
663,663
|
|
||
|
Inventories: Raw materials
|
346,948
|
|
|
326,140
|
|
||
|
Work in process
|
22,357
|
|
|
16,431
|
|
||
|
Finished goods
|
318,512
|
|
|
306,877
|
|
||
|
Total Inventories
|
687,817
|
|
|
649,448
|
|
||
|
Prepaid expenses and other current assets
|
242,870
|
|
|
215,387
|
|
||
|
Total Current Assets
|
1,970,341
|
|
|
1,896,544
|
|
||
|
Property, plant and equipment, at cost
|
2,139,372
|
|
|
2,090,755
|
|
||
|
Accumulated depreciation
|
(1,251,889
|
)
|
|
(1,210,175
|
)
|
||
|
|
887,483
|
|
|
880,580
|
|
||
|
Goodwill
|
1,166,022
|
|
|
1,156,288
|
|
||
|
Other intangible assets, net
|
414,055
|
|
|
415,787
|
|
||
|
Deferred income taxes
|
88,231
|
|
|
99,777
|
|
||
|
Other assets
|
155,144
|
|
|
149,950
|
|
||
|
Total Assets
|
$
|
4,681,276
|
|
|
$
|
4,598,926
|
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
|
|
||||
|
Current Liabilities:
|
|
|
|
||||
|
Short term borrowings
|
$
|
36,819
|
|
|
$
|
6,966
|
|
|
Accounts payable
|
324,262
|
|
|
338,188
|
|
||
|
Accrued payroll and bonus
|
51,194
|
|
|
88,361
|
|
||
|
Dividends payable
|
54,404
|
|
|
54,420
|
|
||
|
Other current liabilities
|
250,073
|
|
|
280,833
|
|
||
|
Total Current Liabilities
|
716,752
|
|
|
768,768
|
|
||
|
Long-term debt
|
1,676,211
|
|
|
1,632,186
|
|
||
|
Deferred gains
|
36,930
|
|
|
37,344
|
|
||
|
Retirement liabilities
|
226,937
|
|
|
228,936
|
|
||
|
Other liabilities
|
245,484
|
|
|
242,398
|
|
||
|
Total Other Liabilities
|
2,185,562
|
|
|
2,140,864
|
|
||
|
Commitments and Contingencies (Note 13)
|
|
|
|
||||
|
Shareholders’ Equity:
|
|
|
|
||||
|
Common stock 12 1/2¢ par value; 500,000,000 shares authorized; 115,858,190 shares issued as of March 31, 2018 and December 31, 2017; and 78,920,199 and 78,947,381 shares outstanding as of March 31, 2018 and December 31, 2017, respectively
|
14,470
|
|
|
14,470
|
|
||
|
Capital in excess of par value
|
166,517
|
|
|
162,827
|
|
||
|
Retained earnings
|
3,947,791
|
|
|
3,870,621
|
|
||
|
Accumulated other comprehensive loss
|
(620,579
|
)
|
|
(637,482
|
)
|
||
|
Treasury stock, at cost (36,937,991 and 36,910,809 shares as of March 31, 2018 and December 31, 2017, respectively)
|
(1,735,049
|
)
|
|
(1,726,234
|
)
|
||
|
Total Shareholders’ Equity
|
1,773,150
|
|
|
1,684,202
|
|
||
|
Noncontrolling interest
|
5,812
|
|
|
5,092
|
|
||
|
Total Shareholders’ Equity including noncontrolling interest
|
1,778,962
|
|
|
1,689,294
|
|
||
|
Total Liabilities and Shareholders’ Equity
|
$
|
4,681,276
|
|
|
$
|
4,598,926
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(AMOUNTS IN THOUSANDS EXCEPT PER SHARE AMOUNTS)
|
2018
|
|
2017
|
||||
|
Net sales
|
$
|
930,928
|
|
|
$
|
828,293
|
|
|
Cost of goods sold
|
525,119
|
|
|
465,210
|
|
||
|
Gross profit
|
405,809
|
|
|
363,083
|
|
||
|
Research and development expenses
|
78,476
|
|
|
72,126
|
|
||
|
Selling and administrative expenses
|
142,644
|
|
|
143,704
|
|
||
|
Amortization of acquisition-related intangibles
|
9,185
|
|
|
7,066
|
|
||
|
Restructuring and other charges, net
|
717
|
|
|
10,143
|
|
||
|
Gain on sales of fixed assets
|
(69
|
)
|
|
(21
|
)
|
||
|
Operating profit
|
174,856
|
|
|
130,065
|
|
||
|
Interest expense
|
16,595
|
|
|
12,807
|
|
||
|
Other (income), net
|
(576
|
)
|
|
(21,229
|
)
|
||
|
Income before taxes
|
158,837
|
|
|
138,487
|
|
||
|
Taxes on income
|
29,421
|
|
|
22,723
|
|
||
|
Net income
|
129,416
|
|
|
115,764
|
|
||
|
Other comprehensive income (loss), after tax:
|
|
|
|
||||
|
Foreign currency translation adjustments
|
14,803
|
|
|
(3,257
|
)
|
||
|
(Losses) on derivatives qualifying as hedges
|
(529
|
)
|
|
(1,751
|
)
|
||
|
Pension and postretirement net liability
|
2,629
|
|
|
3,635
|
|
||
|
Other comprehensive income (loss)
|
16,903
|
|
|
(1,373
|
)
|
||
|
Total comprehensive income
|
$
|
146,319
|
|
|
$
|
114,391
|
|
|
|
|
|
|
||||
|
Net income per share - basic
|
$
|
1.63
|
|
|
$
|
1.46
|
|
|
Net income per share - diluted
|
$
|
1.63
|
|
|
$
|
1.45
|
|
|
Average number of shares outstanding - basic
|
79,018
|
|
|
79,098
|
|
||
|
Average number of shares outstanding - diluted
|
79,393
|
|
|
79,409
|
|
||
|
Dividends declared per share
|
$
|
0.69
|
|
|
$
|
0.64
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Cash flows from operating activities:
|
|
|
|
||||
|
Net income
|
$
|
129,416
|
|
|
$
|
115,764
|
|
|
Adjustments to reconcile to net cash provided by operating activities:
|
|
|
|
||||
|
Depreciation and amortization
|
33,384
|
|
|
26,802
|
|
||
|
Deferred income taxes
|
18,404
|
|
|
(3,766
|
)
|
||
|
Gain on disposal of assets
|
(69
|
)
|
|
(21
|
)
|
||
|
Stock-based compensation
|
7,620
|
|
|
5,819
|
|
||
|
Pension contributions
|
(4,387
|
)
|
|
(25,263
|
)
|
||
|
Product recall claim settlement
|
(12,969
|
)
|
|
—
|
|
||
|
Foreign currency gain on liquidation of entity
|
—
|
|
|
(12,214
|
)
|
||
|
Changes in assets and liabilities, net of acquisitions:
|
|
|
|
||||
|
Trade receivables
|
(61,301
|
)
|
|
(60,858
|
)
|
||
|
Inventories
|
(30,185
|
)
|
|
(109
|
)
|
||
|
Accounts payable
|
(8,435
|
)
|
|
(1,978
|
)
|
||
|
Accruals for incentive compensation
|
(36,583
|
)
|
|
(23,485
|
)
|
||
|
Other current payables and accrued expenses
|
(18,540
|
)
|
|
(7,586
|
)
|
||
|
Other assets
|
(26,035
|
)
|
|
30,284
|
|
||
|
Other liabilities
|
(1,715
|
)
|
|
(24,894
|
)
|
||
|
Net cash (used in) provided by operating activities
|
(11,395
|
)
|
|
18,495
|
|
||
|
Cash flows from investing activities:
|
|
|
|
||||
|
Cash paid for acquisitions, net of cash received
|
(22
|
)
|
|
(138,093
|
)
|
||
|
Additions to property, plant and equipment
|
(33,105
|
)
|
|
(26,662
|
)
|
||
|
Maturity of net investment hedges
|
(2,405
|
)
|
|
1,948
|
|
||
|
Proceeds from disposal of assets
|
293
|
|
|
619
|
|
||
|
Net cash used in investing activities
|
(35,239
|
)
|
|
(162,188
|
)
|
||
|
Cash flows from financing activities:
|
|
|
|
||||
|
Cash dividends paid to shareholders
|
(54,420
|
)
|
|
(50,677
|
)
|
||
|
Increase in revolving credit facility borrowings and overdrafts
|
23,762
|
|
|
100,481
|
|
||
|
Increase in commercial paper
|
29,926
|
|
|
107,441
|
|
||
|
Loss on pre-issuance hedges
|
—
|
|
|
300
|
|
||
|
Employee withholding taxes paid
|
(3,266
|
)
|
|
(3,000
|
)
|
||
|
Purchase of treasury stock
|
(10,617
|
)
|
|
(37,612
|
)
|
||
|
Net cash (used in) provided by financing activities
|
(14,615
|
)
|
|
116,933
|
|
||
|
Effect of exchange rate changes on cash and cash equivalents
|
(1,521
|
)
|
|
2,835
|
|
||
|
Net change in cash and cash equivalents
|
(62,770
|
)
|
|
(23,925
|
)
|
||
|
Cash and cash equivalents at beginning of year
|
368,046
|
|
|
323,992
|
|
||
|
Cash and cash equivalents at end of period
|
$
|
305,276
|
|
|
$
|
300,067
|
|
|
Cash paid for:
|
|
|
|
||||
|
Interest paid, net of amounts capitalized
|
$
|
20,236
|
|
|
$
|
25,590
|
|
|
Income taxes paid
|
$
|
24,939
|
|
|
$
|
20,043
|
|
|
Noncash investing activities:
|
|
|
|
||||
|
Accrued capital expenditures
|
$
|
18,868
|
|
|
$
|
5,433
|
|
|
|
Three Months Ended March 31,
|
||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
(a)
|
||
|
Flavor Compounds
|
449,019
|
|
|
406,164
|
|
|
Fragrance Compounds
|
|
|
|
||
|
Consumer Fragrances
|
280,238
|
|
|
252,695
|
|
|
Fine Fragrances
|
98,395
|
|
|
87,705
|
|
|
Fragrance Ingredients
|
103,276
|
|
|
81,729
|
|
|
Total revenues
|
930,928
|
|
|
828,293
|
|
|
(a)
|
Prior period amounts have not been adjusted based on the modified retrospective method.
|
|
|
Three Months Ended March 31,
|
||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
(a)
|
||
|
Europe, Africa and Middle East
|
309,312
|
|
|
257,684
|
|
|
Greater Asia
|
243,557
|
|
|
222,820
|
|
|
North America
|
241,146
|
|
|
218,828
|
|
|
Latin America
|
136,913
|
|
|
128,961
|
|
|
Total revenues
|
930,928
|
|
|
828,293
|
|
|
(a)
|
Prior period amounts have not been adjusted based on the modified retrospective method.
|
|
(DOLLARS IN THOUSANDS)
|
March 31, 2018
|
|
At adoption
|
||
|
Receivables (included in Trade receivables)
|
747,862
|
|
|
677,055
|
|
|
Contract asset - Short term
|
3,839
|
|
|
4,449
|
|
|
|
Three Months Ended March 31,
|
||||
|
(SHARES IN THOUSANDS)
|
2018
|
|
2017
|
||
|
Basic
|
79,018
|
|
|
79,098
|
|
|
Assumed dilution under stock plans
|
375
|
|
|
311
|
|
|
Diluted
|
79,393
|
|
|
79,409
|
|
|
(DOLLARS IN THOUSANDS)
|
Employee-Related Costs
|
|
Other
|
|
Total
|
||||||
|
Balance at December 31, 2017
|
$
|
7,539
|
|
|
$
|
418
|
|
|
$
|
7,957
|
|
|
Additional charges (reversals), net
|
717
|
|
|
—
|
|
|
717
|
|
|||
|
Non-cash charges
|
—
|
|
|
—
|
|
|
—
|
|
|||
|
Payments
|
(1,696
|
)
|
|
—
|
|
|
(1,696
|
)
|
|||
|
Balance at March 31, 2018
|
$
|
6,560
|
|
|
$
|
418
|
|
|
$
|
6,978
|
|
|
(DOLLARS IN THOUSANDS)
|
Goodwill
|
||
|
Balance at December 31, 2017
|
$
|
1,156,288
|
|
|
Acquisitions
|
22
|
|
|
|
Foreign exchange
|
9,712
|
|
|
|
Balance at March 31, 2018
|
$
|
1,166,022
|
|
|
|
March 31,
|
|
December 31,
|
||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Asset Type
|
|
|
|
||||
|
Customer relationships
|
$
|
414,684
|
|
|
$
|
407,636
|
|
|
Trade names & patents
|
39,556
|
|
|
38,771
|
|
||
|
Technological know-how
|
162,515
|
|
|
161,856
|
|
||
|
Other
|
24,909
|
|
|
24,814
|
|
||
|
Total carrying value
|
641,664
|
|
|
633,077
|
|
||
|
Accumulated Amortization
|
|
|
|
||||
|
Customer relationships
|
(111,796
|
)
|
|
(104,800
|
)
|
||
|
Trade names & patents
|
(16,175
|
)
|
|
(15,241
|
)
|
||
|
Technological know-how
|
(79,929
|
)
|
|
(76,766
|
)
|
||
|
Other
|
(19,709
|
)
|
|
(20,483
|
)
|
||
|
Total accumulated amortization
|
(227,609
|
)
|
|
(217,290
|
)
|
||
|
Other intangible assets, net
|
$
|
414,055
|
|
|
$
|
415,787
|
|
|
(DOLLARS IN THOUSANDS)
|
Effective Interest Rate
|
|
March 31, 2018
|
|
December 31, 2017
|
|||||
|
Senior notes - 2007
(1)
|
6.40% - 6.82%
|
|
|
$
|
249,800
|
|
|
$
|
249,765
|
|
|
Senior notes - 2013
(1)
|
3.39
|
%
|
|
298,747
|
|
|
298,670
|
|
||
|
Euro Senior notes - 2016
(1)
|
1.99
|
%
|
|
611,030
|
|
|
589,848
|
|
||
|
Senior notes - 2017
(1)
|
4.50
|
%
|
|
492,880
|
|
|
492,819
|
|
||
|
Credit facility
|
LIBOR + 1.125%
|
|
(2)
|
24,617
|
|
|
—
|
|
||
|
Commercial paper
|
—
|
%
|
(3)
|
29,926
|
|
|
—
|
|
||
|
Bank overdrafts and other
|
|
|
5,973
|
|
|
7,993
|
|
|||
|
Deferred realized gains on interest rate swaps
|
|
|
57
|
|
|
57
|
|
|||
|
|
|
|
1,713,030
|
|
|
1,639,152
|
|
|||
|
Less: Short term borrowings
(4)
|
|
|
(36,819
|
)
|
|
(6,966
|
)
|
|||
|
|
|
|
$
|
1,676,211
|
|
|
$
|
1,632,186
|
|
|
|
(1)
|
Amount is net of unamortized discount and debt issuance costs.
|
|
(2)
|
Represents the rate on drawn down and outstanding balances. Deferred debt issuance costs are immaterial.
|
|
(3)
|
The effective interest rate of commercial paper issuances fluctuate as short term interest rates and demand fluctuate, and deferred debt issuance costs are immaterial. Additionally, the effective interest rate of commercial paper is not meaningful as issuances do not materially differ from short term interest rates.
|
|
(4)
|
Includes bank borrowings, commercial paper, overdrafts and current portion of long-term debt.
|
|
|
Three Months Ended March 31,
|
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Equity-based awards
|
$
|
7,620
|
|
|
$
|
5,819
|
|
|
Liability-based awards
|
155
|
|
|
1,753
|
|
||
|
Total stock-based compensation expense
|
7,775
|
|
|
7,572
|
|
||
|
Less: tax benefit
|
(1,563
|
)
|
|
(2,213
|
)
|
||
|
Total stock-based compensation expense, after tax
|
$
|
6,212
|
|
|
$
|
5,359
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Net sales:
|
|
|
|
||||
|
Flavors
|
$
|
449,019
|
|
|
$
|
406,164
|
|
|
Fragrances
|
481,909
|
|
|
422,129
|
|
||
|
Consolidated
|
$
|
930,928
|
|
|
$
|
828,293
|
|
|
Segment profit:
|
|
|
|
||||
|
Flavors
|
$
|
111,564
|
|
|
$
|
94,556
|
|
|
Fragrances
|
93,277
|
|
|
77,875
|
|
||
|
Global expenses
|
(23,825
|
)
|
|
(16,293
|
)
|
||
|
Operational Improvement Initiatives (a)
|
(1,026
|
)
|
|
(621
|
)
|
||
|
Acquisition Related Costs (b)
|
514
|
|
|
(8,788
|
)
|
||
|
Integration Related Costs (c)
|
—
|
|
|
(1,192
|
)
|
||
|
Tax Assessment (d)
|
—
|
|
|
(5,350
|
)
|
||
|
Restructuring and Other Charges, net (e)
|
(717
|
)
|
|
(10,143
|
)
|
||
|
Gain on Sale of Assets
|
69
|
|
|
21
|
|
||
|
FDA Mandated Product Recall (f)
|
(5,000
|
)
|
|
—
|
|
||
|
Operating profit
|
174,856
|
|
|
130,065
|
|
||
|
Interest expense
|
(16,595
|
)
|
|
(12,807
|
)
|
||
|
Other income (expense)
|
576
|
|
|
21,229
|
|
||
|
Income before taxes
|
$
|
158,837
|
|
|
$
|
138,487
|
|
|
(a)
|
For 2018, represents accelerated depreciation related to a plant relocation in India and a lab closure in Taiwan. For 2017, represents accelerated depreciation and idle labor costs in Hangzhou, China.
|
|
(b)
|
For 2018, represents adjustments to the contingent consideration payable for PowderPure, and transaction costs related to Fragrance Resources and PowderPure within Selling and administrative expenses. For 2017, represents the amortization of inventory "step-up" related to the acquisitions of David Michael and Fragrance Resources, included in cost of goods sold and transaction costs related to the acquisitions of David Michael, Fragrance Resources and PowderPure, included in Selling and administrative expenses.
|
|
(c)
|
Represents costs related to the integration of the David Michael and Fragrance Resources acquisitions.
|
|
(d)
|
Represents the reserve for payment of a tax assessment related to commercial rent for prior periods.
|
|
(e)
|
Represents severance costs related to the 2017 Productivity Program and Taiwan lab closure.
|
|
(f)
|
Represents management's best estimate of losses related to the previously disclosed FDA mandated recall.
|
|
(DOLLARS IN THOUSANDS)
|
U.S. Plans
|
|
Location of Pension Benefit (Income)
|
||||||
|
Three Months Ended March 31,
|
|
||||||||
|
2018
|
|
2017
|
|
||||||
|
Service cost for benefits earned
|
$
|
596
|
|
|
$
|
698
|
|
|
Included as a component of Operating Profit
|
|
Interest cost on projected benefit obligation
|
4,790
|
|
|
4,560
|
|
|
Included as a component of Other Income (Expense), net
|
||
|
Expected return on plan assets
|
(7,739
|
)
|
|
(9,246
|
)
|
|
Included as a component of Other Income (Expense), net
|
||
|
Net amortization and deferrals
|
1,549
|
|
|
1,793
|
|
|
Included as a component of Other Income (Expense), net
|
||
|
Net periodic benefit income
|
(804
|
)
|
|
(2,195
|
)
|
|
|
||
|
Defined contribution and other retirement plans
|
2,690
|
|
|
2,255
|
|
|
Included as a component of Operating Profit
|
||
|
Total expense
|
$
|
1,886
|
|
|
$
|
60
|
|
|
|
|
(DOLLARS IN THOUSANDS)
|
Non-U.S. Plans
|
|
Location of Pension Benefit (Income)
|
||||||
|
Three Months Ended March 31,
|
|
||||||||
|
2018
|
|
2017
|
|
||||||
|
Service cost for benefits earned
|
$
|
4,470
|
|
|
$
|
5,514
|
|
|
Included as a component of Operating Profit
|
|
Interest cost on projected benefit obligation
|
4,338
|
|
|
3,848
|
|
|
Included as a component of Other Income (Expense), net
|
||
|
Expected return on plan assets
|
(12,032
|
)
|
|
(12,133
|
)
|
|
Included as a component of Other Income (Expense), net
|
||
|
Net amortization and deferrals
|
2,972
|
|
|
3,923
|
|
|
Included as a component of Other Income (Expense), net
|
||
|
Net periodic benefit (income) cost
|
(252
|
)
|
|
1,152
|
|
|
|
||
|
Defined contribution and other retirement plans
|
1,551
|
|
|
1,297
|
|
|
Included as a component of Operating Profit
|
||
|
Total expense
|
$
|
1,299
|
|
|
$
|
2,449
|
|
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Service cost for benefits earned
|
$
|
195
|
|
|
$
|
221
|
|
|
Interest cost on projected benefit obligation
|
654
|
|
|
588
|
|
||
|
Net amortization and deferrals
|
(1,189
|
)
|
|
(1,046
|
)
|
||
|
Total postretirement benefit income
|
$
|
(340
|
)
|
|
$
|
(237
|
)
|
|
•
|
Level 1 — Quoted prices for
identical
instruments in active markets.
|
|
•
|
Level 2 — Quoted prices for
similar
instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.
|
|
•
|
Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable
.
|
|
|
March 31, 2018
|
|
December 31, 2017
|
||||||||||||
|
(DOLLARS IN THOUSANDS)
|
Principal
|
|
Fair
Value |
|
Principal
|
|
Fair
Value |
||||||||
|
Cash and cash equivalents
(1)
|
$
|
305,276
|
|
|
$
|
305,276
|
|
|
$
|
368,046
|
|
|
$
|
368,046
|
|
|
Credit facilities and bank overdrafts
(2)
|
30,589
|
|
|
30,589
|
|
|
7,993
|
|
|
7,993
|
|
||||
|
Commercial paper
(2)
|
29,926
|
|
|
29,926
|
|
|
—
|
|
|
—
|
|
||||
|
Long-term debt:
(3)
|
|
|
|
|
|
|
|
||||||||
|
Senior notes - 2007
|
250,000
|
|
|
285,062
|
|
|
250,000
|
|
|
293,232
|
|
||||
|
Senior notes - 2013
|
300,000
|
|
|
297,535
|
|
|
300,000
|
|
|
304,219
|
|
||||
|
Euro Senior notes - 2016
|
615,400
|
|
|
642,921
|
|
|
594,400
|
|
|
627,782
|
|
||||
|
Senior notes - 2017
|
500,000
|
|
|
497,689
|
|
|
500,000
|
|
|
525,906
|
|
||||
|
(1)
|
The carrying amount of cash and cash equivalents approximates fair value due to the short maturity of those instruments.
|
|
(2)
|
The carrying amount approximates fair value as the interest rate is reset frequently based on current market rates as well as the short maturity of those instruments.
|
|
(3)
|
The fair value of the Company's long-term debt was calculated using discounted cash flows applying current interest rates and current credit spreads based on its own credit risk.
|
|
(DOLLARS IN THOUSANDS)
|
March 31, 2018
|
|
December 31, 2017
|
||||
|
Forward currency contracts
|
$
|
777,134
|
|
|
$
|
896,947
|
|
|
Interest rate swaps
|
$
|
150,000
|
|
|
$
|
150,000
|
|
|
|
March 31, 2018
|
||||||||||
|
(DOLLARS IN THOUSANDS)
|
Fair Value of
Derivatives Designated as Hedging Instruments |
|
Fair Value of
Derivatives Not Designated as Hedging Instruments |
|
Total Fair
Value |
||||||
|
Derivative assets
(a)
|
|
|
|
|
|
||||||
|
Foreign currency contracts
|
$
|
1,053
|
|
|
$
|
6,307
|
|
|
$
|
7,360
|
|
|
Derivative liabilities
(b)
|
|
|
|
|
|
||||||
|
Foreign currency contracts
|
$
|
6,425
|
|
|
$
|
743
|
|
|
$
|
7,168
|
|
|
Interest rate swaps
|
3,169
|
|
|
—
|
|
|
3,169
|
|
|||
|
Total Derivative liabilities
|
$
|
9,594
|
|
|
$
|
743
|
|
|
$
|
10,337
|
|
|
|
December 31, 2017
|
||||||||||
|
(DOLLARS IN THOUSANDS)
|
Fair Value of
Derivatives Designated as Hedging Instruments |
|
Fair Value of
Derivatives Not Designated as Hedging Instruments |
|
Total Fair
Value |
||||||
|
Derivative assets
(a)
|
|
|
|
|
|
||||||
|
Foreign currency contracts
|
$
|
1,159
|
|
|
$
|
3,978
|
|
|
$
|
5,137
|
|
|
Derivative liabilities
(b)
|
|
|
|
|
|
||||||
|
Foreign currency contracts
|
$
|
7,842
|
|
|
$
|
4,344
|
|
|
$
|
12,186
|
|
|
Interest rate swaps
|
1,369
|
|
|
—
|
|
|
1,369
|
|
|||
|
Total Derivative liabilities
|
$
|
9,211
|
|
|
$
|
4,344
|
|
|
$
|
13,555
|
|
|
(a)
|
Derivative assets are recorded to Prepaid expenses and other current assets in the Consolidated Balance Sheet.
|
|
(b)
|
Derivative liabilities are recorded as Other current liabilities in the Consolidated Balance Sheet.
|
|
|
|||||||||
|
|
Amount of Gain (Loss)
|
|
Location of Gain (Loss)
Recognized in Income
on Derivative
|
||||||
|
(DOLLARS IN THOUSANDS)
|
For the Three Months Ended March 31,
|
|
|||||||
|
2018
|
|
2017
|
|
||||||
|
Foreign currency contract
|
$
|
(3,615
|
)
|
|
$
|
(10,127
|
)
|
|
Other (income) expense, net
|
|
|
Amount of Gain (Loss)
Recognized in OCI on
Derivative (Effective
Portion)
|
|
Location of Gain
(Loss) Reclassified
from AOCI into Income
(Effective Portion)
|
|
Amount of Gain (Loss)
Reclassified from
Accumulated OCI into
Income (Effective
Portion)
|
||||||||||||
|
|
Three Months Ended March 31,
|
|
|
Three Months Ended March 31,
|
|||||||||||||
|
|
2018
|
|
2017
|
|
|
2018
|
|
2017
|
|||||||||
|
Derivatives in Cash Flow Hedging Relationships:
|
|
|
|
|
|
|
|
|
|
||||||||
|
Foreign currency contracts
|
$
|
(743
|
)
|
|
$
|
(2,948
|
)
|
|
Cost of goods sold
|
|
$
|
(2,193
|
)
|
|
$
|
458
|
|
|
Interest rate swaps
(1)
|
216
|
|
|
1,213
|
|
|
Interest expense
|
|
$
|
(216
|
)
|
|
(188
|
)
|
|||
|
Derivatives in Net Investment Hedging Relationships:
|
|
|
|
|
|
|
|
|
|
||||||||
|
Foreign currency contracts
|
(696
|
)
|
|
(1,046
|
)
|
|
N/A
|
|
—
|
|
|
—
|
|
||||
|
Euro Senior notes - 2016
|
(15,977
|
)
|
|
(11,409
|
)
|
|
N/A
|
|
—
|
|
|
—
|
|
||||
|
Total
|
$
|
(17,200
|
)
|
|
$
|
(14,190
|
)
|
|
|
|
$
|
(2,409
|
)
|
|
$
|
270
|
|
|
(1)
|
Interest rate swaps were entered into as pre-issuance hedges for bond offerings.
|
|
(DOLLARS IN THOUSANDS)
|
Foreign
Currency
Translation
Adjustments
|
|
(Losses) Gains on Derivatives
Qualifying as
Hedges
|
|
Pension and
Postretirement
Liability
Adjustment
|
|
Total
|
||||||||
|
Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2017
|
$
|
(297,416
|
)
|
|
$
|
(10,332
|
)
|
|
$
|
(329,734
|
)
|
|
$
|
(637,482
|
)
|
|
OCI before reclassifications
|
14,803
|
|
|
(2,938
|
)
|
|
—
|
|
|
11,865
|
|
||||
|
Amounts reclassified from AOCI
|
—
|
|
|
2,409
|
|
|
2,629
|
|
|
5,038
|
|
||||
|
Net current period other comprehensive income (loss)
|
14,803
|
|
|
(529
|
)
|
|
2,629
|
|
|
16,903
|
|
||||
|
Accumulated other comprehensive (loss) income, net of tax, as of March 31, 2018
|
$
|
(282,613
|
)
|
|
$
|
(10,861
|
)
|
|
$
|
(327,105
|
)
|
|
$
|
(620,579
|
)
|
|
(DOLLARS IN THOUSANDS)
|
Foreign
Currency
Translation
Adjustments
|
|
(Losses) Gains on
Derivatives
Qualifying as
Hedges
|
|
Pension and
Postretirement
Liability
Adjustment
|
|
Total
|
||||||||
|
Accumulated other comprehensive (loss) income, net of tax, as of December 31, 2016
|
$
|
(352,025
|
)
|
|
$
|
7,604
|
|
|
$
|
(335,674
|
)
|
|
$
|
(680,095
|
)
|
|
OCI before reclassifications
|
8,957
|
|
|
(1,481
|
)
|
|
—
|
|
|
7,476
|
|
||||
|
Amounts reclassified from AOCI
|
(12,214
|
)
|
(a)
|
(270
|
)
|
|
3,635
|
|
|
(8,849
|
)
|
||||
|
Net current period other comprehensive income (loss)
|
(3,257
|
)
|
|
(1,751
|
)
|
|
3,635
|
|
|
(1,373
|
)
|
||||
|
Accumulated other comprehensive (loss) income, net of tax, as of March 31, 2017
|
$
|
(355,282
|
)
|
|
$
|
5,853
|
|
|
$
|
(332,039
|
)
|
|
$
|
(681,468
|
)
|
|
|
Three Months Ended March 31,
|
|
Affected Line Item in the
Consolidated Statement of Income and Comprehensive Income |
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
|
|||||
|
(Losses) gains on derivatives qualifying as hedges
|
|
|
|
|
|
||||
|
Foreign currency contracts
|
$
|
(2,506
|
)
|
|
$
|
524
|
|
|
Cost of goods sold
|
|
Interest rate swaps
|
(216
|
)
|
|
(188
|
)
|
|
Interest expense
|
||
|
Tax
|
313
|
|
|
(66
|
)
|
|
Provision for income taxes
|
||
|
Total
|
$
|
(2,409
|
)
|
|
$
|
270
|
|
|
Total, net of income taxes
|
|
(Losses) gains on pension and postretirement liability adjustments
|
|
|
|
|
|
||||
|
Prior service cost
|
$
|
1,772
|
|
|
$
|
1,753
|
|
|
(a)
|
|
Actuarial losses
|
(5,103
|
)
|
|
(6,423
|
)
|
|
(a)
|
||
|
Tax
|
702
|
|
|
1,035
|
|
|
Provision for income taxes
|
||
|
Total
|
$
|
(2,629
|
)
|
|
$
|
(3,635
|
)
|
|
Total, net of income taxes
|
|
(a)
|
The amortization of prior service cost and actuarial loss is included in the computation of net periodic benefit cost. Refer to Note 14 of our
2017
Form 10-K for additional information regarding net periodic benefit cost.
|
|
|
Three Months Ended March 31,
|
|
|
|||||||
|
(DOLLARS IN THOUSANDS EXCEPT PER SHARE AMOUNTS)
|
2018
|
|
2017
|
|
Change
|
|||||
|
Net sales
|
$
|
930,928
|
|
|
$
|
828,293
|
|
|
12
|
%
|
|
Cost of goods sold
|
525,119
|
|
|
465,210
|
|
|
13
|
%
|
||
|
Gross profit
|
405,809
|
|
|
363,083
|
|
|
|
|||
|
Research and development (R&D) expenses
|
78,476
|
|
|
72,126
|
|
|
9
|
%
|
||
|
Selling and administrative (S&A) expenses
|
142,644
|
|
|
143,704
|
|
|
(1
|
)%
|
||
|
Amortization of acquisition-related intangibles
|
9,185
|
|
|
7,066
|
|
|
30
|
%
|
||
|
Restructuring and other charges, net
|
717
|
|
|
10,143
|
|
|
(93
|
)%
|
||
|
Gain on sales of fixed assets
|
(69
|
)
|
|
(21
|
)
|
|
229
|
%
|
||
|
Operating profit
|
174,856
|
|
|
130,065
|
|
|
|
|||
|
Interest expense
|
16,595
|
|
|
12,807
|
|
|
30
|
%
|
||
|
Other (income) expense, net
|
(576
|
)
|
|
(21,229
|
)
|
|
(97
|
)%
|
||
|
Income before taxes
|
158,837
|
|
|
138,487
|
|
|
|
|||
|
Taxes on income
|
29,421
|
|
|
22,723
|
|
|
29
|
%
|
||
|
Net income
|
$
|
129,416
|
|
|
$
|
115,764
|
|
|
12
|
%
|
|
Diluted EPS
|
$
|
1.63
|
|
|
$
|
1.45
|
|
|
12
|
%
|
|
Gross margin
|
43.6
|
%
|
|
43.8
|
%
|
|
(20
|
)
|
||
|
R&D as a percentage of sales
|
8.4
|
%
|
|
8.7
|
%
|
|
(30
|
)
|
||
|
S&A as a percentage of sales
|
15.3
|
%
|
|
17.3
|
%
|
|
(200
|
)
|
||
|
Operating margin
|
18.8
|
%
|
|
15.7
|
%
|
|
310
|
|
||
|
Adjusted operating margin
(1)
|
19.4
|
%
|
|
18.9
|
%
|
|
50
|
|
||
|
Effective tax rate
|
18.5
|
%
|
|
16.4
|
%
|
|
210
|
|
||
|
Segment net sales
|
|
|
|
|
|
|||||
|
Flavors
|
$
|
449,019
|
|
|
$
|
406,164
|
|
|
11
|
%
|
|
Fragrances
|
481,909
|
|
|
422,129
|
|
|
14
|
%
|
||
|
Consolidated
|
$
|
930,928
|
|
|
$
|
828,293
|
|
|
|
|
|
(1)
|
Adjusted operating margin excludes
$6.2 million
of charges related to
operational improvement initiatives
,
restructuring and other charges, net
,
acquisition related costs
,
gain on sale of assets
and an
FDA mandated product recall
for the
three months ended March 31, 2018
, and excludes
$26.1 million
of charges related to
operational improvement initiatives
,
acquisition related costs
,
integration related costs
,
tax assessment
,
restructuring and other charges, net
and
gain on sale of assets
for the
three months ended March 31, 2017
. See "Non-GAAP Financial Measures" below.
|
|
|
|
% Change in Sales - First Quarter 2018 vs. First Quarter 2017
|
||||||||||||||||
|
|
|
Fine Fragrances
|
|
Consumer Fragrances
|
|
Ingredients
|
|
Total Frag.
|
|
Flavors
|
|
Total
|
||||||
|
NOAM
|
Reported
|
10
|
%
|
|
13
|
%
|
|
6
|
%
|
|
11
|
%
|
|
10
|
%
|
|
10
|
%
|
|
EAME
|
Reported
|
7
|
%
|
|
19
|
%
|
|
28
|
%
|
|
17
|
%
|
|
24
|
%
|
|
20
|
%
|
|
|
Currency Neutral
(1)
|
-5
|
%
|
|
5
|
%
|
|
15
|
%
|
|
4
|
%
|
|
11
|
%
|
|
7
|
%
|
|
LA
|
Reported
|
37
|
%
|
|
3
|
%
|
|
26
|
%
|
|
11
|
%
|
|
-2
|
%
|
|
6
|
%
|
|
|
Currency Neutral
(1)
|
35
|
%
|
|
3
|
%
|
|
24
|
%
|
|
11
|
%
|
|
-2
|
%
|
|
6
|
%
|
|
GA
|
Reported
|
-15
|
%
|
|
8
|
%
|
|
56
|
%
|
|
14
|
%
|
|
6
|
%
|
|
9
|
%
|
|
|
Currency Neutral
(1)
|
-17
|
%
|
|
5
|
%
|
|
49
|
%
|
|
11
|
%
|
|
2
|
%
|
|
6
|
%
|
|
Total
|
Reported
|
12
|
%
|
|
11
|
%
|
|
26
|
%
|
|
14
|
%
|
|
11
|
%
|
|
12
|
%
|
|
|
Currency Neutral
(1)
|
4
|
%
|
|
6
|
%
|
|
18
|
%
|
|
8
|
%
|
|
6
|
%
|
|
7
|
%
|
|
(1)
|
Currency neutral sales growth is calculated by translating prior year sales at the exchange rates for the corresponding
2018
period.
|
|
•
|
NOAM Flavors sales growth included the impact of acquisitions and primarily reflected high single-digit growth in Beverage, Sweet and Dairy and low single-digit growth in Savory. Total Fragrances sales growth reflected double-digit gains in Fine Fragrances, Toiletries, Fabric Care and Home Care, as well as high single-digit gains in Hair Care and low single-digit gains in Personal Wash and Fragrance Ingredients.
|
|
•
|
EAME Flavors sales experienced double-digit gains in Beverage and Dairy, high single-digit gains in Savory, and low single-digit gains in Sweet. Total Fragrances sales growth was driven mainly by double-digit growth in Toiletries, Hair Care, Home Care, and Fragrance Ingredients as well as low single-digit growth in Fabric Care. These gains more than offset low single-digit declines in Personal Wash and mid single-digit declines in Fine Fragrances.
|
|
•
|
LA Flavors sales included mid single-digit declines in Beverage and Sweet, which were partially offset by double-digit gains in Savory and low single-digit gains in Dairy. Total Fragrances sales growth reflected double-digit gains in Fragrance Ingredients and Fine Fragrances, mid single-digit gains in Hair Care, Personal Wash and Fabric Care, as well as high single-digit gains in Toiletries. These gains more than offset double-digit declines in Home Care.
|
|
•
|
GA Flavors sales growth included the impact of acquisitions and primarily reflected mid to high single-digit growth in Savory and Sweet, respectively, and low single-digit gains in Dairy, which were only partially offset by mid single-digit declines in Beverage. Total Fragrances sales growth was principally driven by double-digit gains in Fragrance Ingredients and Home Care, high single-digit gains in Fabric care, and mid single-digit gains in Toiletries, which more than offset double-digit declines in Fine Fragrances and low single-digit declines in Personal Wash.
|
|
|
Three Months Ended March 31,
|
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Segment profit:
|
|
|
|
||||
|
Flavors
|
$
|
111,564
|
|
|
$
|
94,556
|
|
|
Fragrances
|
93,277
|
|
|
77,875
|
|
||
|
Global expenses
|
(23,825
|
)
|
|
(16,293
|
)
|
||
|
Operational Improvement Initiatives
|
(1,026
|
)
|
|
(621
|
)
|
||
|
Acquisition Related Costs
|
514
|
|
|
(8,788
|
)
|
||
|
Integration Related Costs
|
—
|
|
|
(1,192
|
)
|
||
|
Tax Assessment
|
—
|
|
|
(5,350
|
)
|
||
|
Restructuring and Other Charges, net
|
(717
|
)
|
|
(10,143
|
)
|
||
|
Gain on Sale of Assets
|
69
|
|
|
21
|
|
||
|
FDA Mandated Product Recall
|
(5,000
|
)
|
|
—
|
|
||
|
Operating profit
|
174,856
|
|
|
130,065
|
|
||
|
Profit margin:
|
|
|
|
||||
|
Flavors
|
24.8
|
%
|
|
23.3
|
%
|
||
|
Fragrances
|
19.4
|
%
|
|
18.4
|
%
|
||
|
Consolidated
|
18.8
|
%
|
|
15.7
|
%
|
||
|
(1)
|
Adjusted EBITDA and Net Debt, which are non-GAAP measures used for these covenants, are calculated in accordance with the definition in the debt agreements. In this context, these measures are used solely to provide information on the extent to which we are in compliance with debt covenants and may not be comparable to adjusted EBITDA and Net Debt used by other companies. Reconciliations of adjusted EBITDA to net income and net debt to total debt are as follows:
|
|
(DOLLARS IN MILLIONS)
|
Twelve Months Ended March 31, 2018
|
||
|
Net income
|
$
|
309.3
|
|
|
Interest expense
|
69.2
|
|
|
|
Income taxes
|
248.1
|
|
|
|
Depreciation and amortization
|
124.6
|
|
|
|
Specified items
(1)
|
46.3
|
|
|
|
Non-cash items
(2)
|
28.2
|
|
|
|
Adjusted EBITDA
|
$
|
825.7
|
|
|
(1)
|
Specified items for the 12 months ended
March 31, 2018
of
$46.3 million
consisted of legal charges/credits, acquisition-related costs, costs associated with product recalls, operational improvement initiative costs, restructuring and other charges, gains on sales of fixed assets, integration-related costs, tax assessment and CTA realization.
|
|
(2)
|
Non-cash items represent all other adjustments to reconcile net income to net cash provided by operations as presented on the Statement of Cash Flows, including gain on disposal of assets and stock-based compensation.
|
|
(DOLLARS IN MILLIONS)
|
March 31, 2018
|
||
|
Total debt
|
$
|
1,713.0
|
|
|
Adjustments:
|
|
||
|
Deferred gain on interest rate swaps
|
1.1
|
|
|
|
Cash and cash equivalents
|
(305.3
|
)
|
|
|
Net debt
|
$
|
1,408.8
|
|
|
Reconciliation of Gross Profit
|
|||||||
|
|
Three Months Ended March 31,
|
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Reported (GAAP)
|
$
|
405,809
|
|
|
$
|
363,083
|
|
|
Operational Improvement Initiatives (a)
|
453
|
|
|
621
|
|
||
|
Acquisition Related Costs (b)
|
—
|
|
|
5,301
|
|
||
|
Integration Related Costs (c)
|
—
|
|
|
88
|
|
||
|
FDA Mandated Product Recall (g)
|
5,000
|
|
|
—
|
|
||
|
Adjusted (Non-GAAP)
|
$
|
411,262
|
|
|
$
|
369,093
|
|
|
Reconciliation of Selling and Administrative Expenses
|
|||||||
|
|
Three Months Ended March 31,
|
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Reported (GAAP)
|
$
|
142,644
|
|
|
$
|
143,704
|
|
|
Acquisition Related Costs (b)
|
514
|
|
|
(3,487
|
)
|
||
|
Integration Related Costs (c)
|
—
|
|
|
(943
|
)
|
||
|
Tax Assessment (d)
|
—
|
|
|
(5,350
|
)
|
||
|
Adjusted (Non-GAAP)
|
$
|
143,158
|
|
|
$
|
133,924
|
|
|
Reconciliation of Operating Profit
|
|||||||
|
|
Three Months Ended March 31,
|
||||||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
||||
|
Reported (GAAP)
|
$
|
174,856
|
|
|
$
|
130,065
|
|
|
Operational Improvement Initiatives (a)
|
1,026
|
|
|
621
|
|
||
|
Acquisition Related Costs (b)
|
(514
|
)
|
|
8,788
|
|
||
|
Integration Related Costs (c)
|
—
|
|
|
1,192
|
|
||
|
Tax Assessment (d)
|
—
|
|
|
5,350
|
|
||
|
Restructuring and Other Charges, net (e)
|
717
|
|
|
10,143
|
|
||
|
Gain on Sale of Assets
|
(69
|
)
|
|
(21
|
)
|
||
|
FDA Mandated Product Recall (g)
|
5,000
|
|
|
—
|
|
||
|
Adjusted (Non-GAAP)
|
$
|
181,016
|
|
|
$
|
156,138
|
|
|
Reconciliation of Net Income
|
|||||||||||||||||||||||||||||||
|
|
Three Months Ended March 31,
|
||||||||||||||||||||||||||||||
|
|
2018
|
|
2017
|
||||||||||||||||||||||||||||
|
(DOLLARS IN THOUSANDS)
|
Income before taxes
|
|
Taxes on income (i)
|
|
Net income
|
|
EPS (j)
|
|
Income before taxes
|
|
Taxes on income (i)
|
|
Net income
|
|
EPS
|
||||||||||||||||
|
Reported (GAAP)
|
$
|
158,837
|
|
|
$
|
29,421
|
|
|
$
|
129,416
|
|
|
1.63
|
|
|
$
|
138,487
|
|
|
$
|
22,723
|
|
|
$
|
115,764
|
|
|
$
|
1.45
|
|
|
|
Operational Improvement Initiatives (a)
|
1,026
|
|
|
294
|
|
|
732
|
|
|
0.01
|
|
|
621
|
|
|
155
|
|
|
466
|
|
|
0.01
|
|
||||||||
|
Acquisition Related Costs (b)
|
(514
|
)
|
|
(134
|
)
|
|
(380
|
)
|
|
—
|
|
|
8,788
|
|
|
3,138
|
|
|
5,650
|
|
|
0.07
|
|
||||||||
|
Integration Related Costs (c)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,191
|
|
|
362
|
|
|
829
|
|
|
0.01
|
|
||||||||
|
Tax Assessment (d)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
5,350
|
|
|
1,892
|
|
|
3,458
|
|
|
0.04
|
|
||||||||
|
Restructuring and Other Charges, net (e)
|
717
|
|
|
169
|
|
|
548
|
|
|
0.01
|
|
|
10,143
|
|
|
2,967
|
|
|
7,176
|
|
|
0.09
|
|
||||||||
|
Gain on Sale of Assets
|
(69
|
)
|
|
(17
|
)
|
|
(52
|
)
|
|
—
|
|
|
(21
|
)
|
|
(7
|
)
|
|
(14
|
)
|
|
—
|
|
||||||||
|
CTA Realization (f)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(12,214
|
)
|
|
—
|
|
|
(12,214
|
)
|
|
(0.15
|
)
|
||||||||
|
FDA Mandated Product Recall (g)
|
5,000
|
|
|
1,196
|
|
|
3,804
|
|
|
0.05
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
U.S. Tax Reform (h)
|
—
|
|
|
(649
|
)
|
|
649
|
|
|
0.01
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Adjusted (Non-GAAP)
|
$
|
164,997
|
|
|
$
|
30,280
|
|
|
$
|
134,717
|
|
|
$
|
1.69
|
|
|
$
|
152,345
|
|
|
$
|
31,230
|
|
|
$
|
121,115
|
|
|
$
|
1.52
|
|
|
(a)
|
For 2018, represents accelerated depreciation related to a plant relocation in India and a lab closure in Taiwan. For 2017, represents accelerated depreciation and idle labor costs in Hangzhou, China.
|
|
(b)
|
For 2018, represents adjustments to the contingent consideration payable for PowderPure, and transaction costs related to Fragrance Resources and PowderPure within Selling and administrative expenses. For 2017, represents the amortization of inventory "step-up" related to the acquisitions of David Michael and Fragrance Resources, included in cost of goods sold and transaction costs related to the acquisitions of David Michael, Fragrance Resources and PowderPure, included in Selling and administrative expenses.
|
|
(c)
|
Represents costs related to the integration of the David Michael and Fragrance Resources acquisitions.
|
|
(d)
|
Represents the reserve for payment of a tax assessment related to commercial rent for prior periods.
|
|
(e)
|
Represents severance costs related to the 2017 Productivity Program and Taiwan lab closure.
|
|
(f)
|
Represents the release of CTA related to the liquidation of a foreign entity.
|
|
(g)
|
Represents management's best estimate of losses related to the previously disclosed FDA mandated recall.
|
|
(h)
|
Represents charges incurred related to enactment of certain U.S. tax legislation changes in December 2017.
|
|
(i)
|
The income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable for which the tax expense (benefit) was calculated at 0%. For first quarter of 2018, these non-GAAP adjustments were not subject to foreign tax credits or valuation allowances, but to the extent that such factors are applicable to any future non-GAAP adjustments we will take such factors into consideration in calculating the tax expense (benefit).
|
|
(j)
|
The sum of these items does not foot due to rounding.
|
|
|
Three Months Ended March 31,
|
||
|
|
2018
|
|
2017
|
|
Operating Profit:
|
|
|
|
|
% Change - Reported (GAAP)
|
34%
|
|
(21)%
|
|
Items impacting comparability
(1)
|
(19)%
|
|
18%
|
|
% Change - Adjusted (Non-GAAP)
|
16%
|
|
(3)%
|
|
Currency Impact
|
(4)%
|
|
5%
|
|
% Change Year-over-Year - Currency Neutral Adjusted (Non-GAAP)**
|
12%
|
|
2%
|
|
|
Three Months Ended March 31,
|
||
|
(DOLLARS IN THOUSANDS)
|
2018
|
|
2017
|
|
PowderPure
|
$690
|
|
$—
|
|
Fragrance Resources
|
1,959
|
|
1,257
|
|
David Michael
|
1,131
|
|
595
|
|
Lucas Meyer
|
1,973
|
|
1,859
|
|
Ottens Flavors
|
1,571
|
|
1,571
|
|
•
|
the impact of the planned acquisition of Frutarom;
|
|
•
|
our ability to effectively compete in our market, and to successfully develop new products that appeal to our customers and consumers;
|
|
•
|
our ability to provide our customers with innovative, cost-effective products;
|
|
•
|
the impact of a disruption in our manufacturing operations;
|
|
•
|
the impact of the BASF supply chain disruption on the supply and price of a key ingredient in 2018;
|
|
•
|
the impact of the recently-enacted Tax Act on our effective tax rate in 2018 and beyond;
|
|
•
|
our ability to react in a timely manner to changes in the consumer products industry related to health and wellness;
|
|
•
|
our ability to benefit from our investments and expansion in emerging markets;
|
|
•
|
our ability to comply with, and the costs associated with compliance with, U.S. and foreign environmental protection laws;
|
|
•
|
our ability to realize the expected cost savings and efficiencies from our profitability improvement initiatives and the optimization of our manufacturing facilities;
|
|
•
|
volatility and increases in the price of raw materials, energy and transportation;
|
|
•
|
our ability to maintain the integrity of our raw materials, supply chain and finished goods, and comply with applicable regulations;
|
|
•
|
uncertainties regarding the outcome of, or funding requirements, related to litigation or settlement of pending litigation, uncertain tax positions or other contingencies;
|
|
•
|
the impact of changes in our tax rates, tax liabilities, the adoption of new United States or international tax legislation, or changes in existing tax laws; and
|
|
•
|
our ability to successfully estimate the impact of certain accounting and tax matters.
|
|
•
|
we have incurred and will continue to incur costs relating to the planned acquisition (including significant legal and financial advisory fees) and many of these costs are payable by us whether or not the planned acquisition is completed;
|
|
•
|
matters relating to the planned acquisition (including integration planning) may require substantial commitments of time and resources by our management team, which could otherwise have been devoted to our historical core businesses or other opportunities that may have been beneficial to us;
|
|
•
|
we may be subject to legal proceedings related to the acquisition or the failure to complete the acquisition;
|
|
•
|
the failure to consummate the acquisition may result in negative publicity and a negative impression of us in the investment community; and
|
|
•
|
any disruptions to our business resulting from the announcement and pendency of the acquisition, including any adverse changes in our relationships with our customers, suppliers and employees, may continue or intensify in the event the merger is not consummated.
|
|
•
|
potential disruption of, or reduced growth in, our historical core businesses, due to diversion of management attention and uncertainty with our current customer and supplier relationships;
|
|
•
|
challenges arising from the expansion of our product offerings into adjacencies with which we have limited experience, including flavor ingredients, food additives and nutraceuticals;
|
|
•
|
challenges arising from the expansion into those Frutarom jurisdictions where we do not currently operate or have significant operations;
|
|
•
|
coordinating and integrating research and development teams across technologies and products to enhance product development while reducing costs;
|
|
•
|
consolidating and integrating corporate, information technology, finance and administrative infrastructures, and integrating and harmonizing business systems, which may be more difficult than anticipated due to the significant number of acquisitions completed by Frutarom over the past few years;
|
|
•
|
coordinating sales and marketing efforts to effectively position our capabilities and the direction of product development;
|
|
•
|
difficulties in achieving anticipated cost savings, synergies, business opportunities and growth prospects from combining Frutarom's business with our business;
|
|
•
|
limitations prior to the completion of the acquisition on the ability of management of our company and of Frutarom to conduct planning regarding the integration of the two companies;
|
|
•
|
the increased scale and complexity of our operations resulting from the acquisition;
|
|
•
|
retaining key employees, suppliers and other partners of our company and Frutarom;
|
|
•
|
retaining and efficiently managing Frutarom’s expanded and decentralized customer base;
|
|
•
|
obligations that we will have to counterparties of Frutarom that arise as a result of the change in control of Frutarom;
|
|
•
|
difficulties in anticipating and responding to actions that may be taken by competitors in response to the transaction; and
|
|
•
|
the assumption of and exposure to unknown or contingent liabilities of Frutarom.
|
|
Period
|
Total Number of
Shares
Repurchased
(1)
|
|
Average
Price Paid
per Share
|
|
Total Number of
Shares Purchased as
Part of Publicly
Announced Program
|
|
Approximate Dollar Value
of Shares That May Yet
be Purchased Under the
Program
|
||||||
|
January 1 - 31, 2018
|
24,553
|
|
|
$
|
153.91
|
|
|
24,553
|
|
|
$
|
291,362,668
|
|
|
February 1 - 28, 2018
|
23,861
|
|
|
143.28
|
|
|
23,861
|
|
|
287,943,855
|
|
||
|
March 1 - 31, 2018
|
27,381
|
|
|
138.02
|
|
|
27,381
|
|
|
284,164,750
|
|
||
|
Total
|
75,795
|
|
|
$
|
144.82
|
|
|
75,795
|
|
|
$
|
284,164,750
|
|
|
(1)
|
Shares were repurchased pursuant to the Company’s share repurchase program. Authorization of the repurchase program may be modified, suspended, or discontinued at any time. On May 7, 2018, we announced plans to suspend share repurchases until our deleveraging target is met following our planned acquisition of Frutarom.
|
|
3(ii)
|
|
Bylaws of International Flavors & Fragrances Inc., effective as of May 3, 2018, incorporated by reference to Exhibit 3(ii) to the Registrant's Current Report on Form 8-K filed on May 3, 2018.
|
|
12
|
|
Statement re: Computation of Ratios.
|
|
31.1
|
|
Certification of Andreas Fibig pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
31.2
|
|
Certification of Richard A. O'Leary pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32
|
|
Certification of Andreas Fibig and Richard A. O'Leary pursuant to 18 U.S.C. Section 1350 as adopted pursuant to the Sarbanes-Oxley Act of 2002.
|
|
101.INS
|
|
XBRL Instance Document
|
|
101.SCH
|
|
XBRL Taxonomy Extensions Schema
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
|
Number
|
|
Description
|
|
3(ii)
|
|
|
|
12
|
|
|
|
31.1
|
|
|
|
31.2
|
|
|
|
32
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
101.SCH
|
|
XBRL Taxonomy Extensions Schema
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
|
Dated:
|
|
May 7, 2018
|
By:
|
|
/s/ Andreas Fibig
|
|
|
|
|
|
|
Andreas Fibig
|
|
|
|
|
|
|
Chairman of the Board and Chief Executive Officer
|
|
|
|
|
|
|
|
|
Dated:
|
|
May 7, 2018
|
By:
|
|
/s/ Richard A. O'Leary
|
|
|
|
|
|
|
Richard A. O'Leary
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
Customers
| Customer name | Ticker |
|---|---|
| The Estée Lauder Companies Inc. | EL |
| L Brands, Inc. | LB |
| Revlon, Inc. | REV |
Suppliers
| Supplier name | Ticker |
|---|---|
| Stepan Company | SCL |
| Sensient Technologies Corporation | SXT |
| Tredegar Corporation | TG |
| Flotek Industries, Inc. | FTK |
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|